SCHEMBL2862306

SCHEMBL2862306

CN1CCN(CCNc2ccc3c(c2)[nH]c(=O)c2c(N)n(-c4ccccc4)nc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KHK P50053 1/20 0.45
TDP2 O95551 1/20 0.41
ABL1 P00519 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
LYN P07948 1/20 0.41
SRC P12931 1/20 0.41
MAPK14 Q16539 1/20 0.41
KAT2B Q92831 1/20 0.40
PDGFRB P09619 3/20 0.40
FGFR1 P11362 3/20 0.40
KDR P35968 3/20 0.40
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868580 0.96 KHK (0.42) KHKTDP2ABL1LCKFYN
SCHEMBL2872630 0.91 HTR7 (0.42) KHKTDP2KAT2BPDGFRBFGFR1
SCHEMBL2862297 0.87 TERT (0.52) KHKALDH1A1LMNAMAPTADORA2A
SCHEMBL2862861 0.87 MAP4K4 (0.38) KHKTDP2ABL1LCKFYN
SCHEMBL2856171 0.87 FGFR1 (0.38) SRCFGFR1MEN1KMT2AMAPT
SCHEMBL2869212 0.87 HTR7 (0.43) KHKTDP2SRCPDGFRBFGFR1
SCHEMBL2864188 0.86 PARP1 (0.49) KHKALDH1A1GAALMNAADORA2A
SCHEMBL14375296 0.83 PARP1 (0.43) KHKTDP2ABL1LCKFYN
SCHEMBL14375231 0.81 TDP2 (0.41) TDP2ABL1LCKFYNLYN
SCHEMBL2860907 0.78 PIK3CD (0.44) KDM4EHSD17B10ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KHK 192/4885TDP2 3548/4885ABL1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.